Jiuzhitong announced that its invested company, GALAXIS TECH Group Co., Ltd., was listed on the Main Board of the Hong Kong Stock Exchange on March 24. The company's investment cost was 26.6 million yuan. Following the issuance, Jiuzhitong holds a total of 15.6226 million shares, representing 3.65% of the post-issuance share capital.
Weiguang Biotechnology received approval from the National Medical Products Administration for clinical trials of its subcutaneous human immunoglobulin product for treating Primary Immunodeficiency Diseases.
Zhewen Pictures plans to invest 200 million yuan to participate in establishing a film industry fund with a total committed capital of 1.009 billion yuan. Zhewen's contribution will represent 19.82% of the total.
Tianjin Port reported that for the year 2025, operating revenue reached 12.792 billion yuan, a 5.98% year-on-year increase, while net profit was 981 million yuan, a decrease of 1.30%. The company proposed a cash dividend of 1.02 yuan per 10 shares (before tax).
Jiuli Special Materials announced a share repurchase plan of 1.5 to 2 billion yuan, with a maximum price of 50 yuan per share, aiming to repurchase 3 to 4 million shares, representing 0.31% to 0.41% of the total share capital.
Evergrande Hi-Tech plans to increase capital in its wholly-owned subsidiary, Shenzhen Baole Interactive Technology Co., Ltd., by 50 million yuan using its own funds. The subsidiary's registered capital will increase from 30 million yuan to 80 million yuan.
Ha'erbin Air Conditioning's controlling shareholder, Harbin Industrial Investment Group, plans to extend its share acquisition period by six months to October 27, 2026, due to market conditions, funding arrangements, and frozen accounts. The original plan was to acquire 1% to 2% of shares.
Kelun Pharmaceutical announced that its subsidiary, Kelun-Botech, received NMPA approval for clinical trials of its novel bispecific antibody-drug conjugate SKB103 for treating advanced solid tumors.
Changchun High & New Technology Industry's subsidiary, Gensci, received NMPA acceptance for the clinical trial application of its GenSci161 injection for non-infectious uveitis. Separately, the FDA granted Orphan Drug Designation to its GenSci128 tablets for gastric cancer treatment.
Jing'an Protein adjusted the upper limit for its share repurchase price from 30.68 yuan per share to 46.25 yuan per share.
Sanquan Food announced a share repurchase plan of 75 million to 150 million yuan, with a maximum price of 13.5 yuan per share.
China National Medicines' subsidiary signed a 10.5 million yuan contract to acquire the marketing authorization for a pharmaceutical product.
Gan & Lee Pharmaceuticals received approval for a new clinical trial indication for its drug Bofenglutide targeting obstructive sleep apnea in adult obese patients.
Keqian Biology plans to sign a cooperative R&D agreement with Huazhong Agricultural University for a vaccine project, involving a payment of 1 million yuan.
Guofa Shares announced that a major shareholder's 3.4% stake will be judicially auctioned due to a loan contract dispute, which may lead to a change in the controlling shareholder.
China Telecom reported a 0.1% increase in 2025 operating revenue to 523.925 billion yuan and a 0.5% increase in net profit to 33.185 billion yuan. The company proposed a dividend of 0.908 yuan per 10 shares (before tax).
Huadian Engineering signed an EPC contract valued at approximately 827 million yuan for a project.
Salubris received NMPA approval to conduct clinical trials for its SAL0145 injection targeting MASH.
Three Squirrels announced a share repurchase plan of 100 million to 200 million yuan, with a maximum price of 32.34 yuan per share, aiming to repurchase between 0.7698% and 1.5396% of its total shares.
Sinomach Precision Industry's subsidiary terminated a customized plant leasing cooperation agreement.
Jianlin Home plans to invest 24.99 million yuan to establish an investment fund focusing on high-end manufacturing and advanced technology.
Bori Medicine reported positive Phase I clinical trial results for its weight loss drug BGM0504 tablets in both China and the US.
Jinchengxin signed a contract valued at approximately 470 million yuan for a mining project.
Chang Aluminum's subsidiary won a bid for a project valued at 184 million yuan.
Guan Nong Shares received a cash dividend of 446 million yuan from an invested company.
AECC Aero Science and Technology announced the resignation of two non-independent directors.
Lummy Pharmaceutical's injectable Aztreonam passed consistency evaluation and received supplementary approval.
Pumen Technology received a medical device registration certificate for a fully automated specific protein analyzer.
Yuekang Pharma's subsidiary received FDA approval for clinical trials of its YKYY018 inhalation aerosol for human metapneumovirus.
Zhejiang Yotrio plans to establish a new branch in Toumen Port.
Tron Technology's controlling shareholder pledged 0.96% of shares for financing.
Lummy Pharmaceutical received approval for a supplementary application for its injectable Aztreonam.
Fengfan Shares plans to transfer a 60% equity stake in an affiliated company via public listing.
Comments